Skip to content
Loading...

Become part of the next generation of EASL’s leadership!

Are you deeply engaged in hepatology and science and ready to get involved in EASL’s governance?     EASL is now looking to fill the following positions:   EASL Vice-Secretary  Three Educational Committee Members  Three Policy and Public Health Committee Members  Three Young Investigators Task Force Members…

Read more

EASL policy statement on the use of COVID-19 vaccines in people with chronic liver disease, hepatobiliary cancer, and liver transplant recipients

9 February 2021 By end-January 2021, COVID-19, the systemic disease caused by the pandemic spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), accounted for 2.2 million deaths worldwide and for 100 million individuals infected, according to estimates from the…

Read more

New breakthrough in advanced HCC

Digital Liver Cancer Summit 2021: New follow-up data from a landmark study of liver cancer patients treated with a combination of atezolizumab and bevacizumab has shown the longest ever survival time in a frontline phase 3 trial of systemic therapy…

Read more

Looking towards bright horizons for 2021

This year has been unlike any other. COVID-19 brought unimaginable challenges to the medical community, placing you at the forefront of the pandemic. The year 2020 posed unique questions to those of us treating liver patients and focusing on liver diseases. …

Read more
Back To Top